#United States #New York #AI Integration #Scott Evangelista #TRINITY

Trinity's CEO Scott Evangelista on AI in Life Sciences Commercialization

In a recent interview on New to The Street TV, CEO Scott Evangelista of Trinity showcased the company's 30-year legacy in life sciences commercialization while highlighting the transformative power of artificial intelligence (AI). Broadcast live from the floor of the New York Stock Exchange, Evangelista argued that the real value of AI lies not in experimental applications but in its practical use in making crucial commercial decisions.

Trinity has firmly established itself as a leader in marrying human expertise with cutting-edge technology in the healthcare market. Evangelista emphasized that the integration of deep knowledge in commercialization with a specialized technology platform has enabled Trinity to navigate the complexities of bringing innovative therapies to market successfully. Understanding that the common concern among life sciences leaders is how to successfully implement AI, Evangelista made it clear that AI must be complemented by human insight for meaningful impact.

Throughout the interview, he championed Trinity's TrinityEDGE™ platform as a pivotal asset that leverages data effectively to meet clients' needs. He explained that data on its own is not useful; rather, it is the expert-driven questions that teach the technology how to provide actionable insights. The platform's ability is further illustrated by two key examples: the AI Readiness Benchmark and InsightsEDGE™ | Digital Twins.

Trinity's AI Readiness Benchmark assesses life sciences organizations' readiness for AI adoption, often revealing that many companies struggle with unorganized legacy data systems. In contrast, InsightsEDGE™ enhances the efficiency of brand and field teams through simulated interactions with synthetic physician and payer personas, which can quickly validate messaging strategies without the lengthy waits typically associated with traditional fieldwork.

Scott Evangelista's insights reflect Trinity's commitment to leading in the intersection of scientific knowledge and technological innovation. Highlighting their strategy over the past year, he noted how the company has aggressively advanced its portfolio by implementing new technologies and research initiatives, cementing their role as a trusted partner for pharmaceutical, biotech, and medtech companies.

As Trinity looks toward future challenges and opportunities in the life sciences sector, they remain dedicated to providing invaluable support for their clients. With an impressive 30-year legacy of experience in the commercial landscape, Trinity continues to redefine industry standards by integrating human and artificial intelligence to drive effective commercialization strategies.

For more details, watch the full interview here.

About Trinity

Trinity empowers life sciences commercialization by combining human expertise with advanced technology. For over three decades, major pharmaceutical and biotech companies worldwide have relied on Trinity’s insights and strategies to ensure successful product launches and impactful patient outcomes. Encompassing a team of 1,300 professionals across 14 global offices, Trinity symbolizes excellence in quality, responsiveness, and client relationships.